Safe Orthopaedics, a company founded in 2010 in Paris, France, develops and markets a range of sterile implants and associated single-use surgical instruments. The company has received approval from the Australian regulatory authorities for its SteriSpine devices and has entered into a distribution agreement with SSJ Health that covers Australia and New Zealand.
Spine Surgery Innovator Safe Orthopaedics Now Down Under

SSJ Health is a leading supplier of spinal and orthopedic products in Australia and New Zealand, according to the press release. The group works directly with surgeons and hospitals in the region. SSJ Health CEO Craig Setter said, “Safe Orthopaedics sterile, single use instruments and leading implants have the potential to revolutionize spinal surgery here. They will eliminate the risk of infection from the reuse of surgical instruments, cut hospital operating costs and facilitate increased reactivity to emergency surgeries. We believe these products will change the way surgeons and hospitals operate, disrupting and dominating the Australian and New Zealand spinal surgery market.”
Safe Orthopaedics’ Interim CEO Pierre Dumouchel said, “This approval is a major step forward for us because it marks the introduction of our technologies in the Asia-Pacific region, the world’s second-largest market, which is experiencing the highest growth rate in the world, estimated at 8.2% over the 2015-2020 period. It is the product of a partnership with SSJ Health, and we aim to achieve rapid uptake of our SteriSpine PS and SteriSpine LC ranges in Australia and New Zealand.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.